Champions Biotechnology Partners to Establish Agreements for Preclinical Evaluation of Oncology Drugs

Arlington, VA – December 18, 2008 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established agreements with Centocor Research & Development, Inc., for the preclinical evaluation of certain therapeutic agents in Centocor’s clinical development pipeline. As part of the agreements, Centocor will utilize Champions Biotechnology’s Biomerk Tumorgrafts to evaluate promising antibodies.

“Studies suggest that our Biomerk Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients. A growing number of pharmaceutical and biotechnology companies are beginning to recognize the predictive potential of Biomerk Tumorgrafts,” said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. “Centocor has an impressive track record in the research, development, and commercialization of human therapeutic agents and we are delighted to enter into these agreements with the company.”